April 06, 2017
RealWorld Dynamix™: Biologic Switching in IBD US 2017
Ulcerative Colitis (UC) and Crohn’s disease (CD) are common inflammatory bowel diseases, currently affecting the lives of 1.4 million Americans. The introduction of biologics has changed the face of treatment for moderate to severe patients, and biologic switching in both UC and CD over the past 12 months is predictive of future market shape and brand shares.
The study blends physician survey data with patient record data to understand how the new products are being used by physicians and for which patient types. RealWorld Dynamix™ also captures physician’s perspectives about new agents in development and the impact they will have on the current treatment paradigm.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.